Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a biotechnology company focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. This news page aggregates company announcements, clinical updates, regulatory developments, and financial disclosures related to Iovance’s TIL platform and commercial activities.
Readers can find news about Amtagvi, which Iovance describes as the first FDA-approved T cell therapy for a solid tumor indication, as well as updates on its use in advanced melanoma and other solid tumors. Coverage includes information on Health Canada’s conditional approval of Amtagvi for certain patients with unresectable or metastatic melanoma, and ongoing work to expand access through treatment centers and international markets.
The feed also features interim data from key clinical trials, such as registrational Phase 2 studies of lifileucel in advanced non-small cell lung cancer and other solid tumors, along with reports on next-generation programs like gene-edited TIL therapies and modified IL-2 analogs. Corporate news items include quarterly financial result announcements, conference presentations, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and capital markets transactions described in SEC filings.
Investors, analysts, and healthcare professionals can use this page to follow how Iovance communicates progress on its TIL pipeline, commercial execution for Amtagvi and Proleukin, and interactions with regulators. Regularly reviewing these updates provides context on the company’s development trajectory and its efforts to advance TIL-based immuno-oncology therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Iovance Biotherapeutics (NASDAQ: IOVA), a leader in T cell-based cancer therapies, announced upcoming presentations at key conferences. On April 24, 2023, a fireside chat will take place at Chardan's 7th Annual Genetic Medicine and Cell Therapy Manufacturing Summit. Following this, a chat is scheduled for May 2, 2023, at H.C. Wainwright BioConnect in New York. The JMP Securities Life Sciences Conference will feature a presentation on May 16, 2023. Live and archived webcasts will be available on the company’s investor relations site. Iovance is focused on delivering tumor infiltrating lymphocyte therapies, particularly lifileucel, which shows promise as a one-time treatment for metastatic melanoma. The company is committed to innovating cell therapies to enhance cancer patient outcomes.
Iovance Biotherapeutics has submitted its rolling Biologics License Application (BLA) for lifileucel to the U.S. FDA, marking a significant milestone in the development of T cell-based therapies for cancer.
Lifileucel is aimed at treating patients with advanced melanoma who have not responded to prior therapies. This submission is backed by positive data from the C-144-01 clinical trial.
Iovance plans to support a full approval via the TILVANCE-301 trial, combining lifileucel with pembrolizumab. The FDA has 60 days to review the BLA, with potential for expedited approval.
Iovance Biotherapeutics (NASDAQ: IOVA) announced its participation in multiple upcoming conferences, highlighting its focus on T cell-based cancer immunotherapies. Key events include the H.C. Wainwright Cell Therapy Virtual Conference (February 28), Cowen Health Care Conference (March 7), Oppenheimer 33rd Annual Healthcare Conference (March 14), and Barclays 2023 Global Healthcare Conference (March 15). These presentations aim to showcase Iovance's innovative tumor infiltrating lymphocyte (TIL) therapies, particularly lifileucel for metastatic melanoma. Live and archived webcasts will be accessible on their investor relations webpage.
Iovance Biotherapeutics (NASDAQ: IOVA) reported its fourth quarter and full year 2022 financial results on February 28, 2023, highlighting progress in its BLA submission for lifileucel in advanced melanoma. The company plans to finalize this submission in 1Q23, receiving FDA approval for commercialization. A notable acquisition of Proleukin® aims to enhance revenue, streamline supply chains, and lower clinical costs. Financially, Iovance reported a net loss of $105.3 million for Q4 2022, up from $99.3 million in Q4 2021, while the total annual net loss increased to $395.9 million from $342.3 million. The cash position stands at approximately $669.8 million, sufficient to fund operations through mid-2024.